CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies. However, CAR immunotherapy in solid tumors lags significantly behind. Some of the major hurdles for CAR immunotherapy in solid tumors include...
Alternative Titles
Full title
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_919452a165e941f4aff22bd24ae2f4c5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_919452a165e941f4aff22bd24ae2f4c5
Other Identifiers
ISSN
1756-9966,0392-9078
E-ISSN
1756-9966
DOI
10.1186/s13046-022-02327-z
